Verinata Health, Inc.'s verifi® Prenatal Test Expanded to Include Option to Test for Fetal Aneuploidy in Twin Pregnancies  
10/14/2013 9:21:08 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) today announced that Verinata Health, an Illumina company, will offer a new test option for its non-invasive verifi® prenatal test.1 Physicians will now be able to use the verifi® prenatal test for women pregnant with twins through natural or assisted reproductive methods. The verifi® prenatal test for twins can detect trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and the presence of a Y chromosome in the fetuses. “The verifi® prenatal test was validated using the largest twin population study of over 100 maternal samples, more than any other NIPT method,” said Richard Rava, Ph.D., Vice President of Research and Development for Verinata. “We have incorporated new algorithms into the verifi® test to optimize detection of aneuploidies. Unlike other methods available today, our innovative approach to account for lower fetal fraction in twins ensures accurate, reliable results and the industry’s lowest test failure rate of 0.07 percent.”

Help employers find you! Check out all the jobs and post your resume.